-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on BeOne Medicines, Raises Price Target to $410

Benzinga·02/27/2026 15:46:20
Listen to the news
Guggenheim analyst Michael Schmidt maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $400 to $410.